Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib and Fulvestrant in Advanced ER+ Breast Cancer
NCT02384746Phase 1Terminated
- Sponsor
- Dartmouth Health
- Start
- Jun 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ixazomib in breast cancer, sponsored by Dartmouth Health. Primary endpoint: Number of participants with adverse events prior to commencing a second cycle of treatment. Started Jun 2015; status: terminated.
02
Drugs
ixazomib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02384746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02384746.